Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hideshima

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Leukemia|April 17, 2009
Ascorbic acid inhibits antitumor activity of bortezomib in vivoG Perrone, T Hideshima, H Ikeda, et al.
Leukemia|September 11, 2009
The use of novel agents in the treatment of relapsed and refractory multiple myelomaJ P Laubach, A Mahindra, C S Mitsiades, et al.
Leukemia|March 16, 2011
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast functionS Vallet, S Pozzi, K Patel, et al.
Oncogene|July 27, 2007
A pivotal role for Mcl-1 in Bortezomib-induced apoptosisK Podar, S L Gouill, J Zhang, et al.
British Journal of Haematology|August 24, 2006
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cellsN Raje, S Kumar, T Hideshima, et al.
Blood|October 26, 2000
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyT Hideshima, D Chauhan, Y Shima, et al.
Leukemia|March 25, 2015
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myelomaS Kikuchi, R Suzuki, H Ohguchi, et al.
Blood|July 4, 2001
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migrationK Podar, Y T Tai, F E Davies, et al.
Leukemia|November 22, 2017
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myelomaA Gullà, T Hideshima, G Bianchi, et al.
Leukemia|June 29, 2013
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKsD Cirstea, T Hideshima, L Santo, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Leukemia|April 17, 2009
Ascorbic acid inhibits antitumor activity of bortezomib in vivoG Perrone, T Hideshima, H Ikeda, et al.
Leukemia|September 11, 2009
The use of novel agents in the treatment of relapsed and refractory multiple myelomaJ P Laubach, A Mahindra, C S Mitsiades, et al.
Leukemia|March 16, 2011
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast functionS Vallet, S Pozzi, K Patel, et al.
Oncogene|July 27, 2007
A pivotal role for Mcl-1 in Bortezomib-induced apoptosisK Podar, S L Gouill, J Zhang, et al.
British Journal of Haematology|August 24, 2006
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cellsN Raje, S Kumar, T Hideshima, et al.
Blood|October 26, 2000
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyT Hideshima, D Chauhan, Y Shima, et al.
Leukemia|March 25, 2015
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myelomaS Kikuchi, R Suzuki, H Ohguchi, et al.
Blood|July 4, 2001
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migrationK Podar, Y T Tai, F E Davies, et al.
Leukemia|November 22, 2017
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myelomaA Gullà, T Hideshima, G Bianchi, et al.
Leukemia|June 29, 2013
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKsD Cirstea, T Hideshima, L Santo, et al.
Pageof 9